Would anyone here really care if the company in order to do the trials needed, and perhaps take in equity partners, raised the authorized shares to 3 or even 4 billions if during the time they did so the DCVax's were approved to be part of the SOC for most solid cancers. I don't see a problem with such dilution provided the gains are being achieved.
This won't happen overnight, it could easily take a decade or longer, but where would we be when it happened. I suspect that our market cap could be as big, or bigger than todays largest BP's, but of course they too would have grown, and some may be our partners. I doubt if we'd come close to the market cap of Apple, they have over 15 billion shares outstanding, but we might have half their market cap, which is a trillion dollar number.
We're doing things very differently than the likes of Apple, Tesla, etc. They drove up the price dramatically, then they did splits to take up the share count. We've issued many shares, now it's time to make those shares worth a lot more money so we can rightfully issued more as needed to support growth and/or achieve equity partners.
We have an Annual Meeting coming up in June. As long as we have UK approval before it would not surprise me at all if we're once again asked to raise the authorized shares. The question is, do they just go to 2 billion, or is it 2.5 or 3 billion. It may be premature to bring in an equity partner, but if we do at some point, many shares well be needed for that alone unless a large part of it comes from shareholders tindering shares. I prefer a partner bringing a lot of money into the company over buying a lot of shareholders shares at a nice premium. The share price should rise to very nearly the price a partner is paying for the shares.
Gary
